KRW 32650.0
(-6.18%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 590.3 Million KRW | -21.4% |
2022 | 751.05 Million KRW | -17.62% |
2021 | 911.67 Million KRW | 229.41% |
2020 | 276.75 Million KRW | 37.9% |
2019 | 200.69 Million KRW | 0.0% |
2018 | - KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | -100.0% |
2014 | 3 Billion KRW | 0.0% |
2013 | - KRW | 0.0% |
2012 | - KRW | -100.0% |
2011 | 6.79 Billion KRW | -21.73% |
2010 | 8.68 Billion KRW | -60.21% |
2009 | 21.81 Billion KRW | -1.79% |
2008 | 22.21 Billion KRW | 102.22% |
2007 | 10.98 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | - KRW | 0.0% |
2024 Q1 | 603.56 Million KRW | -100.0% |
2023 Q3 | 576.75 Million KRW | -14.53% |
2023 Q4 | 590.3 Million KRW | 2.35% |
2023 FY | 590.3 Million KRW | -21.4% |
2023 Q1 | 676.4 Million KRW | -9.94% |
2023 Q2 | 674.77 Million KRW | -0.24% |
2022 FY | 751.05 Million KRW | -17.62% |
2022 Q2 | 726.48 Million KRW | -6.85% |
2022 Q1 | 779.87 Million KRW | -14.46% |
2022 Q4 | 751.05 Million KRW | 15.71% |
2022 Q3 | 649.05 Million KRW | -10.66% |
2021 Q2 | 1.04 Billion KRW | 335.47% |
2021 FY | 911.67 Million KRW | 229.41% |
2021 Q1 | 239.63 Million KRW | -13.41% |
2021 Q3 | 997.91 Million KRW | -4.37% |
2021 Q4 | 911.67 Million KRW | -8.64% |
2020 FY | 276.75 Million KRW | 37.9% |
2020 Q4 | 276.75 Million KRW | -2.47% |
2020 Q1 | 303.08 Million KRW | 51.02% |
2020 Q3 | 283.77 Million KRW | -15.59% |
2020 Q2 | 336.16 Million KRW | 10.91% |
2019 Q4 | 200.69 Million KRW | -0.77% |
2019 FY | 200.69 Million KRW | 0.0% |
2019 Q1 | 613.69 Million KRW | 0.0% |
2019 Q2 | 237.72 Million KRW | -61.26% |
2019 Q3 | 202.25 Million KRW | -14.92% |
2018 Q4 | - KRW | 0.0% |
2018 Q1 | - KRW | 0.0% |
2018 FY | - KRW | 0.0% |
2018 Q2 | - KRW | 0.0% |
2018 Q3 | - KRW | 0.0% |
2017 Q2 | - KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2017 Q4 | - KRW | 0.0% |
2017 Q3 | - KRW | 0.0% |
2017 Q1 | - KRW | 0.0% |
2016 Q3 | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 Q4 | - KRW | 0.0% |
2015 Q1 | 3 Billion KRW | 0.0% |
2015 FY | - KRW | -100.0% |
2015 Q4 | - KRW | 0.0% |
2015 Q3 | - KRW | -100.0% |
2015 Q2 | 3 Billion KRW | 0.0% |
2014 Q1 | - KRW | 0.0% |
2014 FY | 3 Billion KRW | 0.0% |
2014 Q2 | - KRW | 0.0% |
2014 Q4 | 3 Billion KRW | 0.0% |
2014 Q3 | - KRW | 0.0% |
2013 Q4 | - KRW | 0.0% |
2013 FY | - KRW | 0.0% |
2013 Q1 | - KRW | 0.0% |
2013 Q2 | - KRW | 0.0% |
2013 Q3 | - KRW | 0.0% |
2012 FY | - KRW | -100.0% |
2012 Q4 | - KRW | 0.0% |
2012 Q1 | 6.97 Billion KRW | 0.0% |
2011 FY | 6.79 Billion KRW | -21.73% |
2011 Q3 | 30.8 Million KRW | -99.65% |
2011 Q1 | 8.17 Billion KRW | -5.85% |
2011 Q2 | 8.75 Billion KRW | 7.12% |
2010 Q3 | 19.11 Billion KRW | -10.43% |
2010 Q1 | 21.57 Billion KRW | -1.09% |
2010 Q2 | 21.34 Billion KRW | -1.07% |
2010 FY | 8.68 Billion KRW | -60.21% |
2010 Q4 | 8.68 Billion KRW | -54.59% |
2009 FY | 21.81 Billion KRW | -1.79% |
2009 Q4 | 21.81 Billion KRW | -21.09% |
2009 Q3 | 27.64 Billion KRW | 38.16% |
2009 Q2 | 20 Billion KRW | 5.47% |
2009 Q1 | 18.97 Billion KRW | -14.59% |
2008 Q2 | 6.73 Billion KRW | -45.21% |
2008 Q1 | 12.29 Billion KRW | 11.95% |
2008 Q3 | 7.49 Billion KRW | 11.23% |
2008 Q4 | 22.21 Billion KRW | 196.38% |
2008 FY | 22.21 Billion KRW | 102.22% |
2007 Q3 | 13.02 Billion KRW | -6.45% |
2007 Q1 | 10.59 Billion KRW | 0.0% |
2007 Q2 | 13.92 Billion KRW | 31.48% |
2007 FY | 10.98 Billion KRW | 0.0% |
2007 Q4 | 10.98 Billion KRW | -15.69% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Yuyu Pharma, Inc. | 13.64 Billion KRW | 95.672% |
Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.708% |
Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 98.024% |
HANDOK Inc. | 123.78 Billion KRW | 99.523% |
Kukje Pharma Co., Ltd. | 475.74 Million KRW | -24.082% |
Yuhan Corporation | 60.23 Billion KRW | 99.02% |
Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.636% |
SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -479.77% |
Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.28% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 90.243% |
Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 96.813% |
MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 95.309% |
Hana Pharm Co., Ltd. | 1.59 Billion KRW | 63.079% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 95.672% |
Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -393.246% |
REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.512% |
Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 98.155% |
JW Holdings Corporation | 20.65 Billion KRW | 97.142% |
Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 96.018% |
Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 98.032% |
JW Pharmaceutical Corporation | 30 Billion KRW | 98.032% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -169.596% |
Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -1.664% |
Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 98.809% |
Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 86.741% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 95.672% |
Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 96.898% |
Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.368% |
JW Pharmaceutical Corporation | 30 Billion KRW | 98.032% |
Yuhan Corporation | 60.23 Billion KRW | 99.02% |
Jeil Pharma Holdings Inc | 10.5 Billion KRW | 94.378% |
Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 98.538% |
Suheung Co., Ltd. | 74 Billion KRW | 99.202% |
JW Pharmaceutical Corporation | 30 Billion KRW | 98.032% |
Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 85.832% |
Korea United Pharm Inc. | 10.96 Billion KRW | 94.615% |
CKD Bio Corp. | 69.43 Billion KRW | 99.15% |
Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 98.293% |
Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 96.34% |
Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -92.248% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -169.596% |
Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.181% |
Boryung Corporation | 151.7 Billion KRW | 99.611% |
Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.248% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 90.243% |
JW Lifescience Corporation | 168 Million KRW | -251.375% |